Randomizirana procjena terapije protiv COVID-19 - Povijest promjena

WikiSysop: Bot: Automatska zamjena teksta (-{{Cite web +{{Citiranje weba)

2022-01-02T10:16:28Z

Bot: Automatska zamjena teksta (-{{Cite web +{{Citiranje weba)

←Starija inačica		Inačica od 2. siječanj 2022. u 10:16
Redak 1:		Redak 1:
	<!--'''Randomizirana procjena terapije protiv COVID-19'''-->{{Strojni prijevod}}		<!--'''Randomizirana procjena terapije protiv COVID-19'''-->{{Strojni prijevod}}
	'''Randomizirana procjena terapije protiv COVID-19''' ([[Engleski jezik\|eng]]: ''Randomised Evaluation of COVID-19 Therapy'', ''RECOVERY Trial'' ili ''RECOVERY'')<ref>{{~~Cite web~~\|url=http://www.isrctn.com/ISRCTN50189673\|title=ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)\|website=www.isrctn.com}}</ref> veliko je [[Faze kliničkog istraživanja\|kliničko ispitivanje]] mogućih tretmana za ljude u [[Ujedinjeno Kraljevstvo\|Ujedinjenom Kraljevstvu]] primljene u bolnicu s teškom infekcijom [[COVID-19]].<ref name="RECOVERY Home">{{Citiranje weba\|url=https://www.recoverytrial.net/\|title=RECOVERY Trial\|accessdate=17 June 2020}}</ref><ref name="BBC17June20">{{Citiranje weba\|url=https://www.bbc.co.uk/news/health-53077893\|title=Coronavirus: Dexamethasone being used to treat NHS patients today\|accessdate=17 June 2020}}</ref><ref name="NatBio 11May20" /> Od [[2. prosinca]] [[2020.]], ispitivanje je testiralo [[Lijek protiv COVID-19\|devet intervencija]] na odraslima: sedam preuređenih lijekova, jedan novorazvijeni lijek i rekonvalescentna plazma.<ref name="RECOVERY Home" />		'''Randomizirana procjena terapije protiv COVID-19''' ([[Engleski jezik\|eng]]: ''Randomised Evaluation of COVID-19 Therapy'', ''RECOVERY Trial'' ili ''RECOVERY'')<ref>{{Citiranje weba\|url=http://www.isrctn.com/ISRCTN50189673\|title=ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)\|website=www.isrctn.com}}</ref> veliko je [[Faze kliničkog istraživanja\|kliničko ispitivanje]] mogućih tretmana za ljude u [[Ujedinjeno Kraljevstvo\|Ujedinjenom Kraljevstvu]] primljene u bolnicu s teškom infekcijom [[COVID-19]].<ref name="RECOVERY Home">{{Citiranje weba\|url=https://www.recoverytrial.net/\|title=RECOVERY Trial\|accessdate=17 June 2020}}</ref><ref name="BBC17June20">{{Citiranje weba\|url=https://www.bbc.co.uk/news/health-53077893\|title=Coronavirus: Dexamethasone being used to treat NHS patients today\|accessdate=17 June 2020}}</ref><ref name="NatBio 11May20" /> Od [[2. prosinca]] [[2020.]], ispitivanje je testiralo [[Lijek protiv COVID-19\|devet intervencija]] na odraslima: sedam preuređenih lijekova, jedan novorazvijeni lijek i rekonvalescentna plazma.<ref name="RECOVERY Home" />

	== Tretmani ==		== Tretmani ==
Redak 19:		Redak 19:
	* Azitromicin ([[antibiotik]])		* Azitromicin ([[antibiotik]])

	Posljednja tri ogranka bila su zatvorena za nove korisnike nakon što se pokazalo da su neučinkovita<ref name="lop-rit">{{~~Cite web~~\|date=29 June 2020\|title=No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY\|url=https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf\|publisher=RECOVERY Trial: Statement from the Chief Investigators\|access-date=30 June 2020}}</ref><ref name="rec-nobenefit">{{~~Cite web~~\|url=https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19\|title=No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19\|date=2020-06-05\|publisher=Recovery Trial, Nuffield Department of Population Health, University of Oxford, UK\|access-date=2020-06-07}}</ref><ref name="Azithromycin-20201214">{{Citiranje weba \|author1=Peter Horby \|author2=Martin Landray \|title=RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19 \|url=https://www.recoverytrial.net/news/recovery-trial-finds-no-benefit-from-azithromycin-in-patients-hospitalised-with-covid-19 \|publisher=RECOVERY Trial \|access-date=14 December 2020}}</ref>		Posljednja tri ogranka bila su zatvorena za nove korisnike nakon što se pokazalo da su neučinkovita<ref name="lop-rit">{{Citiranje weba\|date=29 June 2020\|title=No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY\|url=https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf\|publisher=RECOVERY Trial: Statement from the Chief Investigators\|access-date=30 June 2020}}</ref><ref name="rec-nobenefit">{{Citiranje weba\|url=https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19\|title=No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19\|date=2020-06-05\|publisher=Recovery Trial, Nuffield Department of Population Health, University of Oxford, UK\|access-date=2020-06-07}}</ref><ref name="Azithromycin-20201214">{{Citiranje weba \|author1=Peter Horby \|author2=Martin Landray \|title=RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19 \|url=https://www.recoverytrial.net/news/recovery-trial-finds-no-benefit-from-azithromycin-in-patients-hospitalised-with-covid-19 \|publisher=RECOVERY Trial \|access-date=14 December 2020}}</ref>

	Deksametazon je bio zatvoren za nove unose za odrasle nakon pozitivnih rezultata.		Deksametazon je bio zatvoren za nove unose za odrasle nakon pozitivnih rezultata.

WikiSysop: Bot: Automatska zamjena teksta (-{{cite web +{{Citiranje weba)

2021-12-22T02:34:48Z

Bot: Automatska zamjena teksta (-{{cite web +{{Citiranje weba)

WikiSysop: Bot: Automatski unos stranica

2021-12-11T09:06:40Z

Bot: Automatski unos stranica

Nova stranica

{{Strojni prijevod}}
'''Randomizirana procjena terapije protiv COVID-19''' ([[Engleski jezik|eng]]: ''Randomised Evaluation of COVID-19 Therapy'', ''RECOVERY Trial'' ili ''RECOVERY'')<ref>{{Cite web|url=http://www.isrctn.com/ISRCTN50189673|title=ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)|website=www.isrctn.com}}</ref> veliko je [[Faze kliničkog istraživanja|kliničko ispitivanje]] mogućih tretmana za ljude u [[Ujedinjeno Kraljevstvo|Ujedinjenom Kraljevstvu]] primljene u bolnicu s teškom infekcijom [[COVID-19]].<ref name="RECOVERY Home">{{cite web|url=https://www.recoverytrial.net/|title=RECOVERY Trial|accessdate=17 June 2020}}</ref><ref name="BBC17June20">{{cite web|url=https://www.bbc.co.uk/news/health-53077893|title=Coronavirus: Dexamethasone being used to treat NHS patients today|accessdate=17 June 2020}}</ref><ref name="NatBio 11May20" /> Od [[2. prosinca]] [[2020.]], ispitivanje je testiralo [[Lijek protiv COVID-19|devet intervencija]] na odraslima: sedam preuređenih lijekova, jedan novorazvijeni lijek i rekonvalescentna plazma.<ref name="RECOVERY Home" />

== Tretmani ==
Sljedeći se tretmani nasumično dodjeljuju hospitaliziranim osobama s teškom infekcijom od COVID-19:<ref name="RECOVERY Home" /><ref name="Recovery Protocol">{{cite web|url=https://www.recoverytrial.net/files/recovery-protocol-v9-1-2020-09-18.pdf|title=Recovery Trial Protocol v9|website=Recovery Trial|accessdate=8 November 2020}}</ref>

* Niske doze deksametazona (steroid koji smanjuje upalu; samo djeca)
* [[Tocilizumab]] (protuupalno)
* Rekonvalescentna plazma (krvna plazma ljudi koji su se oporavili od COVID-19 i koji mogu sadržavati antitijela protiv virusa [[SARS-CoV-2]])
* Intravenski imunoglobulin (samo za djecu)<ref name="Recovery Protocol" />
* REGN-COV2 (koktel od dva antivirusna monoklonska antitijela)
* [[Acetilsalicilna kiselina|Aspirin]]
* [[Kolhicin]] (protuupalni lijek)

Sljedeći tretmani prethodno su bili uključeni u ispitivanje:

* Lopinavir-Ritonavir (lijek za [[HIV]])
* Hidroksiklorokin (koristi se za liječenje malarije i reumatizma)
* Azitromicin ([[antibiotik]])

Posljednja tri ogranka bila su zatvorena za nove korisnike nakon što se pokazalo da su neučinkovita<ref name="lop-rit">{{Cite web|date=29 June 2020|title=No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY|url=https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf|publisher=RECOVERY Trial: Statement from the Chief Investigators|access-date=30 June 2020}}</ref><ref name="rec-nobenefit">{{Cite web|url=https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19|title=No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19|date=2020-06-05|publisher=Recovery Trial, Nuffield Department of Population Health, University of Oxford, UK|access-date=2020-06-07}}</ref><ref name="Azithromycin-20201214">{{cite web |author1=Peter Horby |author2=Martin Landray |title=RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19 |url=https://www.recoverytrial.net/news/recovery-trial-finds-no-benefit-from-azithromycin-in-patients-hospitalised-with-covid-19 |publisher=RECOVERY Trial |access-date=14 December 2020}}</ref>

Deksametazon je bio zatvoren za nove unose za odrasle nakon pozitivnih rezultata.

== Dizajn ==
Ispitivanje RECOVERY je veliko, raznovrsno kontrolirano ispitivanje.<ref name="RECOVERY Home" /> Primarni cilj ispitivanja je "pružiti pouzdane procjene učinka ispitivanih tretmana na smrtnost od svih uzroka u 28 dana nakon prve randomizacije."<ref name="RECOVERY Home" />

To je "otvorena oznaka" studije: ljudi koji se liječe i kliničari koji znaju liječe, koji se tretman primjenjuje.<ref name="RECOVERY Home" /> Riječ je o adaptivnom kliničkom ispitivanju s više ruku. Novi postupci mogu se dodavati u ispitivanje kako odmiču, a drugi "lijekovi" za liječenje zatvoreni za novi upis kad se dobiju rezultati.<ref name="NatBio 11May20">{{cite journal|title=Biggest COVID-19 trial tests repurposed drugs first|url=https://www.nature.com/articles/s41587-020-0528-x|date=11 May 2020|journal=Nature Biotechnology|volume=38|issue=5|accessdate=26 June 2020|doi=10.1038/s41587-020-0528-x|page=510|pmid=32393915|s2cid=218593584|doi-access=free}}</ref>

Protokol ispitivanja razvijen je u ožujku 2020. Dizajn minimizira administrativno opterećenje bolničkog osoblja koje se u to vrijeme suočavalo s velikim brojem primanja COVID-19.<ref name="BBC 20Jun20">{{cite web|url=https://www.bbc.co.uk/news/health-53096736|title=At last some good news about coronavirus|date=20 June 2020|website=BBC News|accessdate=20 June 2020|author1=Fergus Walsh}}</ref><ref name="Protocol">{{cite web|url=https://www.recoverytrial.net/files/recovery-protocol-v11-1-2020-11-21.pdf|title=Randomised evaluation of COVID-19 therapy (RECOVERY) - Trial protocol v11|date=21 Nov 2020|publisher=RECOVERY Trial|accessdate=14 Dec 2020}}</ref>

Kad su ljudi koji su hospitalizirani s COVID-19 uključeni u ispitivanje, automatski se randomiziraju na probno liječenje. Ako bilo koji tretman nije dostupan ili je kontraindiciran ili je definitivno indiciran za tog pacijenta, tada taj tretman nije uključen u postupak randomizacije. Glavna faza randomizacije sastoji se od tri dijela, tako da pacijentima ne može biti dodijeljen nijedan ili jedan ili dva ili tri pokusna tretmana. Ako bolest napreduje, može postojati i druga randomizacija.<ref name="Protocol" />

== Operacije ==
Ispitivanje vode odjeli za zdravlje stanovništva i medicinu [[Nuffield|Nuffielda]] sa [[Sveučilište u Oxfordu|Sveučilišta u Oxfordu]].<ref name="rec-nobenefit" /><ref name="BBC 20Jun20" /> Studiju vode Peter Horby i Martin Landray koji su bili su-glavni istražitelji suđenja.<ref>{{cite web|url=https://www.ukri.org/news/preliminary-trial-results-dexamethasone/|title=Preliminary trial results find dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19 - UK Research and Innovation|website=www.ukri.org|language=en|publisher=UK Research and Innovation|accessdate=19 October 2020}}</ref><ref>{{cite news|last1=editor|first1=Sarah Boseley Health|title=Dexamethasone: low-cost drug helps prevent deaths of sickest coronavirus patients|url=https://www.theguardian.com/world/2020/jun/16/steroid-found-to-help-prevent-deaths-of-sickest-coronavirus-patients|work=The Guardian|date=17 June 2020}}</ref> Ispitivanje se odvija u 176 bolnica NHS-a u [[Ujedinjeno Kraljevstvo|Velikoj Britaniji]], a uključuje tisuće zdravstvenih radnika.<ref>{{cite news|last1=KupferschmidtJul. 2|first1=Kai|title=One U.K. trial is transforming COVID-19 treatment. Why haven't others delivered more results?|url=https://www.sciencemag.org/news/2020/07/one-uk-trial-transforming-covid-19-treatment-why-haven-t-others-delivered-more-results|accessdate=19 October 2020|work=Science|date=2 July 2020|language=en}}</ref>

Ispitivanje je započelo u [[Ožujak|ožujku]] 2020., a predviđeno trajanje je do [[Lipanj|lipnja]] [[2021.]] Od [[Prosinac|prosinca]] [[2020.]] u ispitivanje je bilo uključeno više od 20 000 sudionika COVID-19 primljenih u bolnice u Velikoj Britaniji.<ref name="Azithromycin-20201214" />

== Izvori ==
{{Izvori}}

[[Kategorija:Koronavirus]]
[[Kategorija:Medicina]]

←Starija inačica		Inačica od 22. prosinac 2021. u 02:34
Redak 1:		Redak 1:
	<!--'''Randomizirana procjena terapije protiv COVID-19'''-->{{Strojni prijevod}}		<!--'''Randomizirana procjena terapije protiv COVID-19'''-->{{Strojni prijevod}}
	'''Randomizirana procjena terapije protiv COVID-19''' ([[Engleski jezik\|eng]]: ''Randomised Evaluation of COVID-19 Therapy'', ''RECOVERY Trial'' ili ''RECOVERY'')<ref>{{Cite web\|url=http://www.isrctn.com/ISRCTN50189673\|title=ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)\|website=www.isrctn.com}}</ref> veliko je [[Faze kliničkog istraživanja\|kliničko ispitivanje]] mogućih tretmana za ljude u [[Ujedinjeno Kraljevstvo\|Ujedinjenom Kraljevstvu]] primljene u bolnicu s teškom infekcijom [[COVID-19]].<ref name="RECOVERY Home">{{~~cite web~~\|url=https://www.recoverytrial.net/\|title=RECOVERY Trial\|accessdate=17 June 2020}}</ref><ref name="BBC17June20">{{~~cite web~~\|url=https://www.bbc.co.uk/news/health-53077893\|title=Coronavirus: Dexamethasone being used to treat NHS patients today\|accessdate=17 June 2020}}</ref><ref name="NatBio 11May20" /> Od [[2. prosinca]] [[2020.]], ispitivanje je testiralo [[Lijek protiv COVID-19\|devet intervencija]] na odraslima: sedam preuređenih lijekova, jedan novorazvijeni lijek i rekonvalescentna plazma.<ref name="RECOVERY Home" />		'''Randomizirana procjena terapije protiv COVID-19''' ([[Engleski jezik\|eng]]: ''Randomised Evaluation of COVID-19 Therapy'', ''RECOVERY Trial'' ili ''RECOVERY'')<ref>{{Cite web\|url=http://www.isrctn.com/ISRCTN50189673\|title=ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)\|website=www.isrctn.com}}</ref> veliko je [[Faze kliničkog istraživanja\|kliničko ispitivanje]] mogućih tretmana za ljude u [[Ujedinjeno Kraljevstvo\|Ujedinjenom Kraljevstvu]] primljene u bolnicu s teškom infekcijom [[COVID-19]].<ref name="RECOVERY Home">{{Citiranje weba\|url=https://www.recoverytrial.net/\|title=RECOVERY Trial\|accessdate=17 June 2020}}</ref><ref name="BBC17June20">{{Citiranje weba\|url=https://www.bbc.co.uk/news/health-53077893\|title=Coronavirus: Dexamethasone being used to treat NHS patients today\|accessdate=17 June 2020}}</ref><ref name="NatBio 11May20" /> Od [[2. prosinca]] [[2020.]], ispitivanje je testiralo [[Lijek protiv COVID-19\|devet intervencija]] na odraslima: sedam preuređenih lijekova, jedan novorazvijeni lijek i rekonvalescentna plazma.<ref name="RECOVERY Home" />

	== Tretmani ==		== Tretmani ==
	Sljedeći se tretmani nasumično dodjeljuju hospitaliziranim osobama s teškom infekcijom od COVID-19:<ref name="RECOVERY Home" /><ref name="Recovery Protocol">{{~~cite web~~\|url=https://www.recoverytrial.net/files/recovery-protocol-v9-1-2020-09-18.pdf\|title=Recovery Trial Protocol v9\|website=Recovery Trial\|accessdate=8 November 2020}}</ref>		Sljedeći se tretmani nasumično dodjeljuju hospitaliziranim osobama s teškom infekcijom od COVID-19:<ref name="RECOVERY Home" /><ref name="Recovery Protocol">{{Citiranje weba\|url=https://www.recoverytrial.net/files/recovery-protocol-v9-1-2020-09-18.pdf\|title=Recovery Trial Protocol v9\|website=Recovery Trial\|accessdate=8 November 2020}}</ref>

	* Niske doze deksametazona (steroid koji smanjuje upalu; samo djeca)		* Niske doze deksametazona (steroid koji smanjuje upalu; samo djeca)
Redak 19:		Redak 19:
	* Azitromicin ([[antibiotik]])		* Azitromicin ([[antibiotik]])

	Posljednja tri ogranka bila su zatvorena za nove korisnike nakon što se pokazalo da su neučinkovita<ref name="lop-rit">{{Cite web\|date=29 June 2020\|title=No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY\|url=https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf\|publisher=RECOVERY Trial: Statement from the Chief Investigators\|access-date=30 June 2020}}</ref><ref name="rec-nobenefit">{{Cite web\|url=https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19\|title=No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19\|date=2020-06-05\|publisher=Recovery Trial, Nuffield Department of Population Health, University of Oxford, UK\|access-date=2020-06-07}}</ref><ref name="Azithromycin-20201214">{{~~cite web~~ \|author1=Peter Horby \|author2=Martin Landray \|title=RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19 \|url=https://www.recoverytrial.net/news/recovery-trial-finds-no-benefit-from-azithromycin-in-patients-hospitalised-with-covid-19 \|publisher=RECOVERY Trial \|access-date=14 December 2020}}</ref>		Posljednja tri ogranka bila su zatvorena za nove korisnike nakon što se pokazalo da su neučinkovita<ref name="lop-rit">{{Cite web\|date=29 June 2020\|title=No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY\|url=https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf\|publisher=RECOVERY Trial: Statement from the Chief Investigators\|access-date=30 June 2020}}</ref><ref name="rec-nobenefit">{{Cite web\|url=https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19\|title=No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19\|date=2020-06-05\|publisher=Recovery Trial, Nuffield Department of Population Health, University of Oxford, UK\|access-date=2020-06-07}}</ref><ref name="Azithromycin-20201214">{{Citiranje weba \|author1=Peter Horby \|author2=Martin Landray \|title=RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19 \|url=https://www.recoverytrial.net/news/recovery-trial-finds-no-benefit-from-azithromycin-in-patients-hospitalised-with-covid-19 \|publisher=RECOVERY Trial \|access-date=14 December 2020}}</ref>

	Deksametazon je bio zatvoren za nove unose za odrasle nakon pozitivnih rezultata.		Deksametazon je bio zatvoren za nove unose za odrasle nakon pozitivnih rezultata.
Redak 28:		Redak 28:
	To je "otvorena oznaka" studije: ljudi koji se liječe i kliničari koji znaju liječe, koji se tretman primjenjuje.<ref name="RECOVERY Home" /> Riječ je o adaptivnom kliničkom ispitivanju s više ruku. Novi postupci mogu se dodavati u ispitivanje kako odmiču, a drugi "lijekovi" za liječenje zatvoreni za novi upis kad se dobiju rezultati.<ref name="NatBio 11May20">{{cite journal\|title=Biggest COVID-19 trial tests repurposed drugs first\|url=https://www.nature.com/articles/s41587-020-0528-x\|date=11 May 2020\|journal=Nature Biotechnology\|volume=38\|issue=5\|accessdate=26 June 2020\|doi=10.1038/s41587-020-0528-x\|page=510\|pmid=32393915\|s2cid=218593584\|doi-access=free}}</ref>		To je "otvorena oznaka" studije: ljudi koji se liječe i kliničari koji znaju liječe, koji se tretman primjenjuje.<ref name="RECOVERY Home" /> Riječ je o adaptivnom kliničkom ispitivanju s više ruku. Novi postupci mogu se dodavati u ispitivanje kako odmiču, a drugi "lijekovi" za liječenje zatvoreni za novi upis kad se dobiju rezultati.<ref name="NatBio 11May20">{{cite journal\|title=Biggest COVID-19 trial tests repurposed drugs first\|url=https://www.nature.com/articles/s41587-020-0528-x\|date=11 May 2020\|journal=Nature Biotechnology\|volume=38\|issue=5\|accessdate=26 June 2020\|doi=10.1038/s41587-020-0528-x\|page=510\|pmid=32393915\|s2cid=218593584\|doi-access=free}}</ref>

	Protokol ispitivanja razvijen je u ožujku 2020. Dizajn minimizira administrativno opterećenje bolničkog osoblja koje se u to vrijeme suočavalo s velikim brojem primanja COVID-19.<ref name="BBC 20Jun20">{{~~cite web~~\|url=https://www.bbc.co.uk/news/health-53096736\|title=At last some good news about coronavirus\|date=20 June 2020\|website=BBC News\|accessdate=20 June 2020\|author1=Fergus Walsh}}</ref><ref name="Protocol">{{~~cite web~~\|url=https://www.recoverytrial.net/files/recovery-protocol-v11-1-2020-11-21.pdf\|title=Randomised evaluation of COVID-19 therapy (RECOVERY) - Trial protocol v11\|date=21 Nov 2020\|publisher=RECOVERY Trial\|accessdate=14 Dec 2020}}</ref>		Protokol ispitivanja razvijen je u ožujku 2020. Dizajn minimizira administrativno opterećenje bolničkog osoblja koje se u to vrijeme suočavalo s velikim brojem primanja COVID-19.<ref name="BBC 20Jun20">{{Citiranje weba\|url=https://www.bbc.co.uk/news/health-53096736\|title=At last some good news about coronavirus\|date=20 June 2020\|website=BBC News\|accessdate=20 June 2020\|author1=Fergus Walsh}}</ref><ref name="Protocol">{{Citiranje weba\|url=https://www.recoverytrial.net/files/recovery-protocol-v11-1-2020-11-21.pdf\|title=Randomised evaluation of COVID-19 therapy (RECOVERY) - Trial protocol v11\|date=21 Nov 2020\|publisher=RECOVERY Trial\|accessdate=14 Dec 2020}}</ref>

	Kad su ljudi koji su hospitalizirani s COVID-19 uključeni u ispitivanje, automatski se randomiziraju na probno liječenje. Ako bilo koji tretman nije dostupan ili je kontraindiciran ili je definitivno indiciran za tog pacijenta, tada taj tretman nije uključen u postupak randomizacije. Glavna faza randomizacije sastoji se od tri dijela, tako da pacijentima ne može biti dodijeljen nijedan ili jedan ili dva ili tri pokusna tretmana. Ako bolest napreduje, može postojati i druga randomizacija.<ref name="Protocol" />		Kad su ljudi koji su hospitalizirani s COVID-19 uključeni u ispitivanje, automatski se randomiziraju na probno liječenje. Ako bilo koji tretman nije dostupan ili je kontraindiciran ili je definitivno indiciran za tog pacijenta, tada taj tretman nije uključen u postupak randomizacije. Glavna faza randomizacije sastoji se od tri dijela, tako da pacijentima ne može biti dodijeljen nijedan ili jedan ili dva ili tri pokusna tretmana. Ako bolest napreduje, može postojati i druga randomizacija.<ref name="Protocol" />

	== Operacije ==		== Operacije ==
	Ispitivanje vode odjeli za zdravlje stanovništva i medicinu [[Nuffield\|Nuffielda]] sa [[Sveučilište u Oxfordu\|Sveučilišta u Oxfordu]].<ref name="rec-nobenefit" /><ref name="BBC 20Jun20" /> Studiju vode Peter Horby i Martin Landray koji su bili su-glavni istražitelji suđenja.<ref>{{~~cite web~~\|url=https://www.ukri.org/news/preliminary-trial-results-dexamethasone/\|title=Preliminary trial results find dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19 - UK Research and Innovation\|website=www.ukri.org\|language=en\|publisher=UK Research and Innovation\|accessdate=19 October 2020}}</ref><ref>{{cite news\|last1=editor\|first1=Sarah Boseley Health\|title=Dexamethasone: low-cost drug helps prevent deaths of sickest coronavirus patients\|url=https://www.theguardian.com/world/2020/jun/16/steroid-found-to-help-prevent-deaths-of-sickest-coronavirus-patients\|work=The Guardian\|date=17 June 2020}}</ref> Ispitivanje se odvija u 176 bolnica NHS-a u [[Ujedinjeno Kraljevstvo\|Velikoj Britaniji]], a uključuje tisuće zdravstvenih radnika.<ref>{{cite news\|last1=KupferschmidtJul. 2\|first1=Kai\|title=One U.K. trial is transforming COVID-19 treatment. Why haven't others delivered more results?\|url=https://www.sciencemag.org/news/2020/07/one-uk-trial-transforming-covid-19-treatment-why-haven-t-others-delivered-more-results\|accessdate=19 October 2020\|work=Science\|date=2 July 2020\|language=en}}</ref>		Ispitivanje vode odjeli za zdravlje stanovništva i medicinu [[Nuffield\|Nuffielda]] sa [[Sveučilište u Oxfordu\|Sveučilišta u Oxfordu]].<ref name="rec-nobenefit" /><ref name="BBC 20Jun20" /> Studiju vode Peter Horby i Martin Landray koji su bili su-glavni istražitelji suđenja.<ref>{{Citiranje weba\|url=https://www.ukri.org/news/preliminary-trial-results-dexamethasone/\|title=Preliminary trial results find dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19 - UK Research and Innovation\|website=www.ukri.org\|language=en\|publisher=UK Research and Innovation\|accessdate=19 October 2020}}</ref><ref>{{cite news\|last1=editor\|first1=Sarah Boseley Health\|title=Dexamethasone: low-cost drug helps prevent deaths of sickest coronavirus patients\|url=https://www.theguardian.com/world/2020/jun/16/steroid-found-to-help-prevent-deaths-of-sickest-coronavirus-patients\|work=The Guardian\|date=17 June 2020}}</ref> Ispitivanje se odvija u 176 bolnica NHS-a u [[Ujedinjeno Kraljevstvo\|Velikoj Britaniji]], a uključuje tisuće zdravstvenih radnika.<ref>{{cite news\|last1=KupferschmidtJul. 2\|first1=Kai\|title=One U.K. trial is transforming COVID-19 treatment. Why haven't others delivered more results?\|url=https://www.sciencemag.org/news/2020/07/one-uk-trial-transforming-covid-19-treatment-why-haven-t-others-delivered-more-results\|accessdate=19 October 2020\|work=Science\|date=2 July 2020\|language=en}}</ref>

	Ispitivanje je započelo u [[Ožujak\|ožujku]] 2020., a predviđeno trajanje je do [[Lipanj\|lipnja]] [[2021.]]<!-- <ref name="rec-04381936" /> --> Od [[Prosinac\|prosinca]] [[2020.]] u ispitivanje je bilo uključeno više od 20 000 sudionika COVID-19 primljenih u bolnice u Velikoj Britaniji.<ref name="Azithromycin-20201214" />		Ispitivanje je započelo u [[Ožujak\|ožujku]] 2020., a predviđeno trajanje je do [[Lipanj\|lipnja]] [[2021.]]<!-- <ref name="rec-04381936" /> --> Od [[Prosinac\|prosinca]] [[2020.]] u ispitivanje je bilo uključeno više od 20 000 sudionika COVID-19 primljenih u bolnice u Velikoj Britaniji.<ref name="Azithromycin-20201214" />